Clinical Trial Update: A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study evaluating azacitidine, docetaxel, and prednisone in metastatic prostate cancer was terminated. Results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)

Snippet

Sponsor: University of Miami | Conditions: Prostate Cancer, Pain | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-01-20